



**Fiscal Note**  
**H.B. 106 2nd Sub. (Gray)**  
 2020 General Session  
 Rare Disease Advisory Council  
 by Perry, L. (Perry, Lee.)



**General, Education, and Uniform School Funds**

JR4-4-101

	Ongoing	One-time	Total
Net GF/EF/USF (rev.-exp.)	\$ (38,200)	\$ 0	\$ (38,200)

**State Government**

UCA 36-12-13(2)(c)

Revenues	FY 2020	FY 2021	FY 2022
Total Revenues	\$ 0	\$ 0	\$ 0

Enactment of this legislation likely will not materially impact state revenue.

Expenditures	FY 2020	FY 2021	FY 2022
General Fund	\$ 0	\$ 38,200	\$ 38,200
Total Expenditures	\$ 0	\$ 38,200	\$ 38,200

This legislation appropriates \$9,500 ongoing General Fund to the Department of Health beginning in Fiscal Year 2021 to issue a grant to convene a new Rare Disease Advisory Council which may cost \$38,200 ongoing General Fund to operate. The Department of Health has indicated that it may be able to obtain in-kind donations for the remaining \$28,700 ongoing.

	FY 2020	FY 2021	FY 2022
<b>Net All Funds</b>	<b>\$ 0</b>	<b>\$ (38,200)</b>	<b>\$ (38,200)</b>

**Local Government**

UCA 36-12-13(2)(c)

Enactment of this legislation likely will not result in direct, measurable costs for local governments.

**Individuals & Businesses**

UCA 36-12-13(2)(c)

Enactment of this legislation likely will not result in direct expenditures from tax or fee changes for Utah residents and businesses.

**Regulatory Impact**

UCA 36-12-13(2)(d)

Enactment of this legislation likely will not change the regulatory burden for Utah residents or businesses.

**Performance Note**

JR4-2-404

No performance note required for this bill

**Notes on Notes**

Fiscal notes estimate the direct costs or revenues of enacting a bill. The Legislature uses them to balance the budget. They do not measure a bill's benefits or non-fiscal impacts like opportunity costs, wait times, or inconvenience. A fiscal note is not an appropriation. The Legislature decides appropriations separately.